{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T19:36:20Z","timestamp":1768678580873,"version":"3.49.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We attempt to analyze bone marrow findings and correlation with cytopenia(s) after anti\u2013B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell infusion in this study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Relevant clinicopathologic data, including complete blood counts, neutrophil counts, relevant therapy history, and pre- and posttherapy bone marrow evaluations, were studied in 12 patients who received anti-BCMA CAR T-cell therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Bone marrow findings after CAR T-cell therapy were available in 6 of 12 cases, 3 of which showed markedly hypocellular marrow with either markedly reduced or essentially absent hematopoiesis. One case showed a hypocellular marrow with trilineage hematopoiesis, while the remaining 2 cases showed persistent involvement by plasma cell myeloma. Reticulin stains did not reveal significant fibrosis. Ten patients had anemia, and 8 patients had leukopenia and thrombocytopenia at day 90 posttherapy. Long-term follow-up showed persistent disease in 10 of 12 cases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Prolonged cytopenias occur in most patients after BCMA CAR T-cell therapy with bone marrow evaluations demonstrating associated marked hypocellularity with minimal or no hematopoiesis without an increase in fibrosis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqae083","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T19:29:34Z","timestamp":1721503774000},"page":"641-647","source":"Crossref","is-referenced-by-count":3,"title":["Persistent cytopenias after anti-BCMA CAR T-cell therapy are associated with reduced hematopoietic activity in posttreatment bone marrows"],"prefix":"10.1093","volume":"162","author":[{"given":"Pranav Pramod","family":"Patwardhan","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Pittsburgh Medical Center , Pittsburgh, PA ,","place":["US"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Franz","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Pittsburgh School of Medicine , Pittsburgh, PA ,","place":["US"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounzer","family":"Agha","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Pittsburgh School of Medicine , Pittsburgh, PA ,","place":["US"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Rea","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Pittsburgh Medical Center , Pittsburgh, PA ,","place":["US"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,20]]},"reference":[{"issue":"12","key":"2024121300192019100_CIT0001","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"issue":"9","key":"2024121300192019100_CIT0002","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J."},{"issue":"8","key":"2024121300192019100_CIT0003","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol."},{"issue":"8","key":"2024121300192019100_CIT0004","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med."},{"issue":"9","key":"2024121300192019100_CIT0005","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1158\/1078-0432.CCR-21-3803","article-title":"FDA approval summary: idecabtagene vicleucel for relapsed or refractory multiple myeloma","volume":"28","author":"Sharma","year":"2022","journal-title":"Clin Cancer Res."},{"issue":"20","key":"2024121300192019100_CIT0006","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1182\/blood.2022017415","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood."},{"issue":"2","key":"2024121300192019100_CIT0007","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40268-019-0269-9","article-title":"Bortezomib for the treatment of hematologic malignancies: 15 years later","volume":"19","author":"Robak","year":"2019","journal-title":"Drugs R D."},{"issue":"13","key":"2024121300192019100_CIT0008","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","article-title":"Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study","volume":"15","author":"Kumar","year":"2014","journal-title":"Lancet Oncol."},{"issue":"4","key":"2024121300192019100_CIT0009","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.mayocp.2017.01.003","article-title":"Therapy for relapsed multiple myeloma: guidelines from the Mayo stratification for myeloma and risk-adapted therapy","volume":"92","author":"Dingli","year":"2017","journal-title":"Mayo Clin Proc."},{"issue":"8","key":"2024121300192019100_CIT0010","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res."},{"issue":"25","key":"2024121300192019100_CIT0011","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1200\/JCO.19.03237","article-title":"Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T cells in relapsed chronic lymphocytic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol."},{"issue":"10297","key":"2024121300192019100_CIT0012","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet."},{"issue":"1","key":"2024121300192019100_CIT0013","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/ejh.14068","article-title":"Abnormal bone marrow findings in patients following treatment with chimeric antigen receptor-T cell therapy","volume":"112","author":"Yeung","year":"2024","journal-title":"Eur J Haematol."},{"issue":"4","key":"2024121300192019100_CIT0014","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/medsci11040067","article-title":"Bone marrow aplasia after CAR-T-cell therapy for relapsed\/refractory Burkitt\u2019s lymphoma","volume":"11","author":"Kenkel","year":"2023","journal-title":"Med Sci (Basel)"},{"issue":"4","key":"2024121300192019100_CIT0015","doi-asserted-by":"publisher","first-page":"E89","DOI":"10.1002\/ajh.25725","article-title":"Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma","volume":"95","author":"Qasrawi","year":"2020","journal-title":"Am J Hematol."},{"issue":"suppl 1","key":"2024121300192019100_CIT0016","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1182\/blood-2021-148466","article-title":"Bone marrow lymphoid infiltrates and aplasia after CD19-directed CAR T cell therapy in pediatric B-lymphoblastic leukemia","volume":"138","author":"McFerran","year":"2021","journal-title":"Blood."},{"issue":"8","key":"2024121300192019100_CIT0017","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1080\/10428194.2022.2056172","article-title":"Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms","volume":"63","author":"Brudno","year":"2022","journal-title":"Leuk Lymphoma."},{"issue":"1","key":"2024121300192019100_CIT0018","doi-asserted-by":"publisher","first-page":"E20","DOI":"10.1002\/ajh.25664","article-title":"Successful treatment of marrow failure after CARTs for myeloma by the infusion of cryopreserved stem cells","volume":"95","author":"Yan","year":"2020","journal-title":"Am J Hematol."},{"issue":"1","key":"2024121300192019100_CIT0019","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.path.2015.09.006","article-title":"Therapy effect: impact on bone marrow morphology","volume":"9","author":"Li","year":"2016","journal-title":"Surg Pathol Clin."},{"key":"2024121300192019100_CIT0020","doi-asserted-by":"publisher","DOI":"10.1159\/000539134","article-title":"Toxicity of CAR T-cell therapy for multiple myeloma","author":"Afrough","journal-title":"Acta Haematol"},{"key":"2024121300192019100_CIT0021","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19515","article-title":"Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed\/refractory multiple myeloma: results from a prospective comprehensive biomarker study","author":"Zhou","journal-title":"Br J Haematol"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/162\/6\/641\/60882751\/aqae083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/162\/6\/641\/60882751\/aqae083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:19:27Z","timestamp":1734049167000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/162\/6\/641\/7717649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,20]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,7,20]]},"published-print":{"date-parts":[[2024,12,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqae083","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,7,20]]}}}